GW Pharma under pressure despite 65% jump in Epidiolex sales in Q2

GW Pharmaceuticals (NASDAQ:GWPH) Q2 results:

Revenue: $121.3M (+68.5%); Epidiolex sales: $117.7M (+64.6%).

Net loss: ($8.8M) (-111.0%); loss/share: ($0.02) (-109.5%).

Cash flow ops (6 mo.): ($34.3M) (+61.8%).

Shares down 5% after hours.

https://seekingalpha.com/news/3602235-gw-pharma-under-pressure-despite-65-jump-in-epidiolex-sales-in-q2